"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

Florida Cancer Specialists & Research Institute, LLC (FCS) continues to expand the availability of life-changing and ...

Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...

Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive ...

Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto. - The ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.